In situ sprayed bioresponsive immunotherapeutic gel for post-surgical treatment
AssigneeNorth Carolina State University
InventorsZhen GU, Qian CHEN
Life of this patent
Estimating the term…
Abstract
Disclosed are compositions and methods related to bioresponsive hydrogel matrixes comprising fibrinogen encapsulated nanoparticle and thrombin. Disclosed are methods and compositions related to immunotherapeutic bioresponsive gel matrixes and methods of using the same to treat, prevent, and/or inhibit tumor proliferation.
Claims33
An immunotherapeutic bioresponsive gel matrix comprising a first component and a second component;
- wherein gelation of the matrix occurs when the first component comes into contact with the second component;
- and wherein at least one of the components comprises at least one first nanoparticle;
- wherein the at least one first nanoparticle comprises at least one anti-cancer agent, blockade inhibitor, or immunomodulatory agent.
(canceled)
(canceled)
(canceled)
A method of inhibiting metastasis at the site of surgical resection of a cancer tumor comprising administering to the site of the resection, an immunotherapeutic bioresponsive gel matrix comprising a first component and a second component;
- wherein gelation of the matrix occurs when the first component comes into contact with the second component;
- and wherein at least one of the components comprises at least first one nanoparticle;
- wherein the at least one first nanoparticle comprises at least one anti-cancer agent, blockade inhibitor, or immunomodulatory agent.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method of increasing the innate or adaptive immune response to a tumor following resection of the tumor comprising administering to a subject with a tumor an immunotherapeutic bioresponsive gel matrix comprising a first component and a second component;
- wherein gelation of the matrix occurs when the first component comes into contact with the second component;
- and wherein at least one of the components comprises at least one first nanoparticle;
- wherein the at least one first nanoparticle comprises at least one anti-cancer agent, blockade inhibitor, or immunomodulatory agent.
(canceled)
Dependencies are inferred from the claim text.